EyeGate brings second venture round up to $12M

EyeGate Pharma has added $2 million to its second round, bringing the total to $12 million. The Nexus Group provided the new funds. EyeGate is using iontophoresis technology to deliver therapeutics for ocular indications.

- check out the release on EyeGate's second round

Related Articles:
EyeGate opens up U.S. operations. Report
New biotech arrival gains $10M in venture funds. Report

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.